Application of new orally anticoagulants in patients with chronic kidney disease

Abstract

Abstract: Novel oral anticoagulants (NOVACs) as blood coagulation factor inhibitors have exhibited pivotal role in thromboembolic event and ischemic cardiovascular disease. Nevertheless, it's application in chronic kidney disease (CKD) patients of stage 3-5 remains controversial. This paper reviewed currently recommended usage of NOACs in CKD patients of stage 3-5 in the evaluation of anticoagulation related nephropathy, clinical monitoring and assessment of NOACs.

Key words: chronic kidney disease, new oral anticoagulant, embolization

CLC Number:

WANG Xiu-heng, WU Jie, HU Heng-jing. Application of new orally anticoagulants in patients with chronic kidney disease[J]. Basic & Clinical Medicine, 2020, 40(8): 1103-1108.

References

[1] Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial[J]. Circulation, 2016, 134:24-36.
[2] Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial[J]. JAMA Cardiol, 2016, 1:451-460.
[3] Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments[J]. Lancet, 2015, 386:281-291.
[4] Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications[J]. J Am Soc Nephrol, 2009, 20:912-921.
[5] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009,361:1139-1151.
[6] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365:883-891.
[7] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011,365:981-992.
[8] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013,369:2093-2104.
[9] Nielsen PB, Lane DA, Rasmussen LH, et al. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis[J]. Clin Res Cardiol, 2015, 104:418-429.
[10] Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF[J]. Circulation, 2016, 134:37-47.
[11] Heidbuchel H, Verhamme P, Alings M, et al. Updated european heart rhythm association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary[J]. Eur Heart J, 2017, 38:2137-2149.
[12] Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation[J]. Am J Cardiol, 2016, 117:69-75.
[13] Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabiga-tran in asians with nonvalvular atrial fibrillation[J]. J Am Coll Cardiol, 2016, 68:1389-1401.
[14] Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis[J]. Ann Intern Med, 2019, 171:181-189.
[15] Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.[J]. Eur Heart J, 2018, 39:1330-1393.
[16] Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the asia pacific heart rhythm society on stroke prevention in atrial fibrillation[J]. J Arrhythm, 2017, 33:345-367.
[17] Zbigniew K, Hubert S, Andrzej J, et al. Safety of new oral anticoagulants for patients with chronic kidney disease[J]. Curr Pharm Des, 2018, 24:4505-4510.
[18] Yoon CY, Noh J, Jhee JH, et al. Warfarin use in patients with atrial fibrillation undergoing hemodialysis: a nationwide population-based study[J]. Stroke, 2017, 48:2472-2479.
[19] Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis[J]. Circulation, 2014, 129:1196-1203.
[20] Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis[J]. Circulation, 2015, 131:972-979.
[21] Kalaitzidis RG, Duni A, Liapis G, et al. Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity[J]. Int Urol Nephrol, 2017, 49:1401-1407.
[22] Berger R, Salhanick SD, Chase M, et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin[J]. Ann Emerg Med, 2013, 61:475-479.
[23] Chan YH, Yeh YH, See LC, et al. Acute kidney injury in asians with atrial fibrillation treated with dabigatran or warfarin[J]. J Am Coll Cardiol, 2016, 68:2272-2283.
[24] Potpara TS, Lenarczyk R, Larsen TB, et al. Management of atrial fibrillation in patients with chronic kidney disease in europe results of the european heart rhythm association survey[J]. Europace, 2015, 17:1862-1867.